We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

772 hedge funds and large institutions have $29.6B invested in Teva Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 254 increasing their positions, 309 reducing their positions, and 65 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more call options, than puts

Call options by funds: $1.34B | Put options by funds: $589M

14% more capital invested

Capital invested by funds: $26B → $29.6B (+$3.61B)

0.48% more ownership

Funds ownership: 52.26% → 52.74% (+0.48%)

1% less funds holding

Funds holding: 779 → 772 (-7)

8% less first-time investments, than exits

New positions opened: 60 | Existing positions closed: 65

4% less funds holding in top 10

Funds holding in top 10: 49 → 47 (-2)

18% less repeat investments, than reductions

Existing positions increased: 254 | Existing positions reduced: 309

Holders
772
Holders Change
-7
Holders Change %
-0.9%
% of All Funds
22.4%
Holding in Top 10
47
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-4.08%
% of All Funds
1.36%
New
60
Increased
254
Reduced
309
Closed
65
Calls
$1.34B
Puts
$589M
Net Calls
+$755M
Net Calls Change
-$241M

Top Buyers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
+$376M
2
Boston Partners
Boston Partners
Massachusetts
+$259M
3
William Blair & Company
William Blair & Company
Illinois
+$246M
4
BA
BlackRock Advisors
Delaware
+$143M
5
SCM
Scopia Capital Management
New York
+$141M

Top Sellers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
-$500M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$164M
3
Bank of America
Bank of America
North Carolina
-$148M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$132M
5
PC
PointState Capital
New York
-$110M
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
751
Vantage Investment Advisors
Pennsylvania
$11K – – –
CAW
752
Cornerstone Advisors (Washington)
Washington
$10K – – –
TSW
753
Thompson Siegel & Walmsley
Virginia
$10K – – –
DSC
754
Duncker Streett & Co
Missouri
$9K – – –
LWM
755
LBA Wealth Management
Florida
$8K – – –
TCM
756
TD Capital Management
Tennessee
$8K – – –
WCM
757
Wealthcare Capital Management
Virginia
$7K – – –
DBT
758
Dubuque Bank & Trust
Iowa
$5K +$4.77K +90 New
BWFA
759
Baltimore-Washington Financial Advisors
Maryland
$5K +$5.3K +100 New
HCM
760
Horrell Capital Management
Arkansas
$4K – – –
QAM
761
QCI Asset Management
New York
$4K – – –
Manulife (Manufacturers Life Insurance)
762
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.05K -$381K -7,195 -11%
WA
763
WealthTrust-Arizona
Arizona
$3K -$530 -10 -17%
ACS
764
Archford Capital Strategies
Illinois
$3K – – –
GGPS
765
Gary Goldberg Planning Services
New York
$3K – – –
CCS
766
Crosspoint Capital Strategies
California
$3K +$2.65K +50 New
ANBT
767
American National Bank & Trust
Texas
$3K +$3.34K +63 New
NG
768
NatWest Group
United Kingdom
$2.15K -$214K -4,038 -9%
AWM
769
Avior Wealth Management
Nebraska
$2K – – –
WF
770
WealthTrust Fairport
Ohio
$2K – – –
HMS
771
Hanseatic Management Services
New Mexico
$2K +$1.7K +32 New
DFO
772
Duquesne Family Office
New York
– -$65.1M -1,241,000 Closed
SM
773
Sabby Management
Florida
– -$53.7M -1,013,302 Closed
CRAM
774
Claren Road Asset Management
New York
– -$47.2M -900,000 Closed
GTP
775
Global Thematic Partners
New York
– -$43.6M -830,820 Closed
29 30
31
32 33

TEVA Hedge Fund Activity: Q3 2014 in Review

772 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2014, worth a combined $29.6B — up 14% from $26B a quarter earlier.

Sellers outnumbered buyers: 65 funds closed out of TEVA and 60 opened new positions — a net loss of 5 holders — while 309 trimmed existing stakes and 254 added.

The largest buyer was Waddell & Reed Financial, adding an estimated $376M. The largest seller was Norges Bank, cutting an estimated $500M.

  • 772 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2014, down from 779 in Q2 2014.
  • Funds reported $29.6B of Teva Pharmaceuticals stock for Q3 2014, up 14% quarter-over-quarter.
  • 60 funds opened new Teva Pharmaceuticals positions in Q3 2014 and 65 closed out, a net change of -5 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2014 was Waddell & Reed Financial, an estimated $376M added.
  • The largest Teva Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $500M sold.

Based on aggregated 13F filings for Q3 2014.